Appointments

Pacira Biosciences, specialist in non-opioid pain therapies, has appointed Shawn Cross as its chief financial officer. In this role, Mr Cross will take over all responsibility for the company’s financial operations.

“I am proud to join Pacira as I am strongly aligned with the company’s important mission to deliver innovative, non-opioid pain therapies. Pacira is on strong financial footing with a business that is generating significant cash flow driven by three best-in-class, market-leading products. I am excited to work with the Pacira leadership team as we invest in our next phase of growth and beyond,” commented Mr Cross.

His expertise stems from 25 years of experience in the biotech industry, in addition to experience gleaned from investment banking and time served on various boards. He still serves on the board of directors for Cyclo Therapuetics, where he was previously appointed as the chief executive officer after leading the company through a merger with Applied Molecular Transport (AMT). Previously, Mr Cross was managing director for Healthcare Investment Banking at JMP Securities Inc, which followed on from his roles in senior positions at Deutsche Bank Securities and Wells Fargo Securities.

Mr Cross holds a Bachelor of Sciences degree in Kinesiology from the University of California, and an MBA from Colombia Business School, both in the US.

“We are delighted to welcome Shawn as our new chief financial officer and look forward to his leadership and guidance as we invest in long-term growth and value creation while maintaining high standards in resource allocation and execution,” said Frank D Lee, chief executive officer of Pacira BioSciences. “Shawn brings a strong set of experiences in finance and embraces our values to advance our mission to transform the lives of patients.”